Geron Corp (GERN)

2.16
0.02 0.92
NASDAQ : Health Care
Prev Close 2.18
Open 2.17
Day Low/High 2.14 / 2.20
52 Wk Low/High 2.30 / 5.30
Volume 527.24K
Avg Volume 1.05M
Exchange NASDAQ
Shares Outstanding 159.21M
Market Cap 347.09M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Geron Shares Take a Dive After J&J Unit-Led Trial Falters; Endo Closes Higher: Biotech Movers

Geron Shares Take a Dive After J&J Unit-Led Trial Falters; Endo Closes Higher: Biotech Movers

Geron and Endo and were among the biotech stock movers on Aug. 1.

Geron Announces Updates To Imetelstat Clinical Development

Geron Announces Updates To Imetelstat Clinical Development

Conference Call Scheduled for 8:00 a.m. ET on Tuesday, August 1

Commit To Buy Geron Corp. At $2, Earn 12.8% Annualized Using Options

Commit To Buy Geron Corp. At $2, Earn 12.8% Annualized Using Options

Investors eyeing a purchase of Geron Corp. stock, but tentative about paying the going market price of $2.96/share, might benefit from considering selling puts among the alternative strategies at their disposal.

First Week Of December 15th Options Trading For Geron (GERN)

Investors in Geron Corp. saw new options become available this week, for the December 15th expiration.

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

OncoMed Pharmaceuticals, Geron and Akorn were among the biotech stock movers in premarket trading on Monday.

Biotech Premarket Movers: Innoviva, Akebia, Geron

Biotech Premarket Movers: Innoviva, Akebia, Geron

Innoviva, Akebia Therapeutics and Geron were among the biotech stock movers in premarket trading on Tuesday.

Geron Corporation Reports Fourth Quarter And Annual 2016 Financial Results

Conference Call Scheduled for 4:30 p.m. ET Today, March 1

Interesting GERN Call Options For September 15th

Interesting GERN Call Options For September 15th

Investors in Geron Corp. saw new options become available this week, for the September 15th expiration.

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.

Geron Corporation Reports Third Quarter 2016 Financial Results And Recent Events

Geron Corporation Reports Third Quarter 2016 Financial Results And Recent Events

Conference Call Scheduled for 4:30 p.m. EDT Today, November 3

Geron (GERN) Stock Rises on $80 Million Janssen Licensing Deal

Geron (GERN) Stock Rises on $80 Million Janssen Licensing Deal

Geron (GERN) announced on Monday that it agreed to a licensing deal with Janssen Pharmaceuticals worth $80 million.

Geron Provides Update On Imetelstat Trials Being Conducted By Janssen

Geron Provides Update On Imetelstat Trials Being Conducted By Janssen

Conference Call Scheduled for 8:00 a.m. EDT Today, September 12

Geron Corporation Reports Second Quarter 2016 Financial Results And Recent Events

Geron Corporation Reports Second Quarter 2016 Financial Results And Recent Events

Conference Call Scheduled for 4:30 p.m. EDT Today, August 3

TheStreet Quant Rating: D (Sell)